公开(公告)号：US20230203491A1

公开(公告)日：2023-06-29

申请号：US17999399

申请日：2021-05-21

Applicant: BIONEER CORPORATION ,  SIRNAGEN THERAPEUTICS CORPORATION

Inventor： Han-Oh PARK ,  Jangseon KIM ,  Mi Sun LEE ,  Soonja CHOI ,  Eun-Kwang LEE ,  Sang Jin BYUN

IPC: C12N15/113 ,  A61K9/51 ,  A61P31/14 ,  A61P11/00 ,  A61K31/713

CPC classification number: C12N15/1131 ,  A61K9/51 ,  A61P31/14 ,  A61P11/00 ,  A61K31/713 ,  C12N2310/3235 ,  C12N2310/3231 ,  C12N2310/315 ,  C12N2310/312 ,  C12N2310/14 ,  C12N2320/32

Abstract: The present invention relates to: a double-stranded oligonucleotide which can highly specifically and efficiently inhibit the proliferation of Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), preferably a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or a DNA/RNA hybrid; a double-stranded oligonucleotide structure and nanoparticles comprising the double-stranded oligonucleotide; and a use thereof for treating COVID-19.

公开(公告)号：US20230348912A1

公开(公告)日：2023-11-02

申请号：US17998662

申请日：2021-05-13

Applicant: BIONEER CORPORATION ,  SIRNAGEN THERAPEUTICS CORPORATION

Inventor： Jun Hong PARK ,  Han-Oh PARK ,  Sung Il YUN ,  Tae Rim KIM ,  Soo Hyun HWANG ,  Kang SONG ,  Sang Hyuk JUNG ,  Jangseon KIM ,  Mi Sun LEE ,  Soonja CHOI ,  Seung Seob SON

IPC: C12N15/113 ,  A61K48/00 ,  A61K47/60 ,  A61K47/69 ,  A61P3/04

CPC classification number: C12N15/1136 ,  A61K48/0025 ,  A61K47/60 ,  A61K47/6929 ,  A61P3/04

Abstract: The present invention relates to a double-stranded oligonucleotide capable of inhibiting amphiregulin expression in a very specific and highly efficient manner, preferably a double-stranded oligonucleotide comprising a sequence in the form of an RNA/RNA, DNA/DNA or DNA/RNA hybrid, and the use of a double-stranded oligonucleotide structure, which comprises the double-stranded oligonucleotide, and nanoparticles, for preventing or treating obesity.